XSC
ABBV icon

X-Square Capital’s AbbVie ABBV Stock Holding History

X-Square Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.77M Buy
14,964
+750
+5% +$161K 0.96% 28
2026
Q1 		$3.09M Sell
14,214
-1,194
-8% -$265K 1.04% 25
2025
Q4 		$3.52M Sell
15,408
-521
-3% -$119K 1.15% 25
2025
Q3 		$3.69M Buy
15,929
+255
+2% +$51.9K 1.15% 22
2025
Q2 		$2.91M Buy
15,674
+133
+0.9% +$24.7K 1.05% 30
2025
Q1 		$3.26M Buy
15,541
+689
+5% +$134K 1.4% 18
2024
Q4 		$2.64M Buy
14,852
+142
+1% +$26.1K 1.08% 31
2024
Q3 		$2.9M Buy
14,710
+625
+4% +$117K 1.28% 26
2024
Q2 		$2.42M Sell
14,085
-171
-1% -$28.3K 1.12% 30
2024
Q1 		$2.51M Buy
14,256
+8,981
+170% +$1.55M 1.19% 29
2023
Q4 		$817K Buy
5,275
+1,051
+25% +$153K 0.45% 73
2023
Q3 		$569K Hold
4,224
– – 0.38% 82
2023
Q2 		$569K Buy
4,224
+1,950
+86% +$286K 0.38% 82
2023
Q1 		$362K Buy
2,274
+8
+0.4% +$1.22K 0.21% 113
2022
Q4 		$366K Buy
+2,266
New +$347K 0.21% 119

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

X-Square Capital's ABBV Position: Q2 2026 in Review

X-Square Capital increased its AbbVie (ABBV) stake by 5.3% in Q2 2026, buying an estimated $161K and bringing the position to 14,964 shares worth $3.77M. The position accounts for 0.96% of the portfolio, ranked #28.

X-Square Capital first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • X-Square Capital held 14,964 shares of AbbVie worth $3.77M as of Q2 2026.
  • X-Square Capital bought 750 AbbVie shares in Q2 2026, an estimated $161K.
  • AbbVie made up 0.96% of X-Square Capital's portfolio in Q2 2026, its #28 holding.
  • X-Square Capital first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
  • 4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on X-Square Capital's 13F filing for Q2 2026, filed 12 Aug 2026.